ONS ONCC CHEMO
RENEWAL PRACTICE
QUESTIONS AND
CORRECT ANSWERS
GRADED A+ 2025-2026
Neoadjuvant therapy does not increase survival when compared to adjuvant therapy. It
only changes the timing of treatment and can change surgical options if the tumor is
shrunk enough. If this occurs, the patient may only require a lumpectomy plus
radiation therapy instead of needing a mastectomy - ANS-Main benefit of neoadjuvant
chemotherapy (breast cancer patient)
A comprehensive geriatric assessment (CGA) is a multidisciplinary evaluation to assess
life expectancy and risk of morbidity and mortality in the older patient. This
assessment tool would evaluate and include the following areas: functional status,
socioeconomic issues, psychosocial distress, comorbidities, cognitive function,
nutritional status, polypharmacy, and a medication review (NCCN Older Adult
Oncology Guidelines, version 1.2015). - ANS-Due to Mrs. Turner's age and
comorbidities, her oncologist performs a comprehensive geriatric assessment. You
know that this assessment covers all but which of the following:
65 - ANS-The NCCN Older Adult Oncology Guidelines (version 1.2015) provides
information on what is included in a comprehensive geriatric assessment. Currently,
more than 60% of cancers in the United States occur in people age ______and older and
as the oncology world ages, nearly half (46%) of cancer survivors are 70 years of age or
older
Two of the agents (docetaxel and carboplatin) that Mrs. Turner will receive are
categorized as irritants. Docetaxel can cause a significant reaction if it extravasates. It
can lead to edema, erythema, occasional pain and blister formation (ONS Chemo/Bio
guidelines, 2014). That is the most likely reason that Mrs. Turner was given a port for
her treatments. Some patients will receive their treatments through a peripheral IV
, without incident. Just because they are intravenous agents does not mean that a port is
required and needing a port has nothing to do with her being older in age. Since none
of these agents are vesicants, they likely could have been given safely via peripheral
route but having a port placed is OK as well. - ANS-What is your best explanation for
why Mrs. Turner was given a port to receive her chemotherapy?
Irrirtants - ANS-_____________can cause inflammation, pain, and burning but rarely
cause tissue necrosis comparable to a vesicant (unless a large amount or a very high
concentration of the irritant is extravasated).
Vesicants - ANS-_____________can cause blistering and significant pain and tissue
damage and destruction, leading to tissue death.
Non-DNA-binding solutions remain in the local area of the extravasation, which
improves the possibility of drug deactivation.
DNA-binding agents attach to DNA nucleic acids, causing the antagonist to be ingested
cellularly, leading to progressive tissue destruction - ANS-A further classification of an
antineoplastic agent's potential to cause damage is whether its mechanism of action
includes DNA binding.
Bendamustinea
Dactinomycin
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Mechlorethamine
Mitomycin - ANS-DNA Binding Irritants
Amsacrine
Paclitaxel
Vinblastine
Vincristine
RENEWAL PRACTICE
QUESTIONS AND
CORRECT ANSWERS
GRADED A+ 2025-2026
Neoadjuvant therapy does not increase survival when compared to adjuvant therapy. It
only changes the timing of treatment and can change surgical options if the tumor is
shrunk enough. If this occurs, the patient may only require a lumpectomy plus
radiation therapy instead of needing a mastectomy - ANS-Main benefit of neoadjuvant
chemotherapy (breast cancer patient)
A comprehensive geriatric assessment (CGA) is a multidisciplinary evaluation to assess
life expectancy and risk of morbidity and mortality in the older patient. This
assessment tool would evaluate and include the following areas: functional status,
socioeconomic issues, psychosocial distress, comorbidities, cognitive function,
nutritional status, polypharmacy, and a medication review (NCCN Older Adult
Oncology Guidelines, version 1.2015). - ANS-Due to Mrs. Turner's age and
comorbidities, her oncologist performs a comprehensive geriatric assessment. You
know that this assessment covers all but which of the following:
65 - ANS-The NCCN Older Adult Oncology Guidelines (version 1.2015) provides
information on what is included in a comprehensive geriatric assessment. Currently,
more than 60% of cancers in the United States occur in people age ______and older and
as the oncology world ages, nearly half (46%) of cancer survivors are 70 years of age or
older
Two of the agents (docetaxel and carboplatin) that Mrs. Turner will receive are
categorized as irritants. Docetaxel can cause a significant reaction if it extravasates. It
can lead to edema, erythema, occasional pain and blister formation (ONS Chemo/Bio
guidelines, 2014). That is the most likely reason that Mrs. Turner was given a port for
her treatments. Some patients will receive their treatments through a peripheral IV
, without incident. Just because they are intravenous agents does not mean that a port is
required and needing a port has nothing to do with her being older in age. Since none
of these agents are vesicants, they likely could have been given safely via peripheral
route but having a port placed is OK as well. - ANS-What is your best explanation for
why Mrs. Turner was given a port to receive her chemotherapy?
Irrirtants - ANS-_____________can cause inflammation, pain, and burning but rarely
cause tissue necrosis comparable to a vesicant (unless a large amount or a very high
concentration of the irritant is extravasated).
Vesicants - ANS-_____________can cause blistering and significant pain and tissue
damage and destruction, leading to tissue death.
Non-DNA-binding solutions remain in the local area of the extravasation, which
improves the possibility of drug deactivation.
DNA-binding agents attach to DNA nucleic acids, causing the antagonist to be ingested
cellularly, leading to progressive tissue destruction - ANS-A further classification of an
antineoplastic agent's potential to cause damage is whether its mechanism of action
includes DNA binding.
Bendamustinea
Dactinomycin
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Mechlorethamine
Mitomycin - ANS-DNA Binding Irritants
Amsacrine
Paclitaxel
Vinblastine
Vincristine
